Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1453072
PUBLISHER: FirstWord Group | PRODUCT CODE: 1453072
Rheumatoid Arthritis - KOL Insight
PUBLISHED: annual subscription
PAGES:
DELIVERY TIME:
SELECT AN OPTION
While use of anti-TNF therapies remains the first line biologic RA treatment choice, prescribing of IL-6 inhibitors has increased. But do KOLs prefer Roche's Actemra/RoActemra or Sanofi's Kevzara? Experts find Amgen's pipeline anti-CD40 ligand-Tn3 fusion protein dazodalibep to be intriguing, but do they see it finding a place in the crowded RA therapy market? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to the following KOL Bulletins via the Attachments area.
Companies Listed:
|
|
Table of Contents
Executive summary (8)
Treatment algorithm
Research objectives (86)
- Marketed therapies (67)
- Anti-TNFs (Humira, Enbrel, Remicade, Simponi, Cimzia) (8)
- Interleukin-6 inhibitors (Actemra/RoActemra, Kevzara) (10)
- Orencia (abatacept; Bristol Myers Squibb) (10)
- Rituxan/MabThera (rituximab; Biogen/Roche) (8)
- Xeljanz (tofacitinib; Pfizer) (10)
- Olumiant (baricitinib; Incyte/Lilly) (7)
- Rinvoq (upadacitinib; AbbVie) (8)
- Jyseleca (filgotinib; Galapagos) (6)
- Pipeline therapies (5)
- dazodalibep (HZN 4920; Amgen) (5)
- Earlier-stage developments and other factors that may impact RA treatment (12)
- Key insights summary (12)
Appendix (4)
- KOL details (4)
- KOLs from the USA (1)
- KOLs from Europe (2)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.